EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Kidney Organoids in Drug Development: Integrating Technological Advances and Standardization for Effective Implementation

Helen Kearney iD, Silvia M Mihăilă iD, Lorenzo Moroni iD, Carlos Mota iD

Advanced Healthcare Materials · 2026

DOI: 10.1002/adhm.202504719 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Helen Kearney und 3 weiteren Autor:innen. Beteiligte Einrichtung: MERLN Institute for Technology-Inspired Regenerative Medicine, Complex Tissue Regeneration Department, Maastricht University, Maastricht, 6229 ER, th…. Hauptthemen laut MEDLINE: Organoids, Kidney, Drug Development. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 183 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Horizon 2020 Framework Programme, European Union's FET Open program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kidney organoids have emerged as promising in vitro models for studying human kidney development and nephrotoxicity. Despite their potential, limitations in maturation, reproducibility, and scalability have hindered their adoption in current drug development. Recent advances in differentiation protocols, biomaterials formulations, and enabling technologies such as bioprinting, organ‐on‐chip systems, and cell sorting are helping to overcome these challenges. However, further standardization in organoid differentiation, imaging, in silico analysis, and high‐throughput screening automation is required for practical and effective implementation and regulatory alignment. This review provides a comprehensive overview of technological advancements that enhance kidney organoid models, emphasizing the steps needed for their integration into preclinical testing. By focusing on standardization, we highlight how kidney organoids can become reliable tools for future drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OrganoidsKidneyDrug DevelopmentHumansAnimalsCell DifferentiationBioprinting

Stichwörter der Autor:innen

complex in vitro modelsdrug induced kidney injurykidney organoidsnephrotoxicitystandardization

Autor:innen und Institutionen

  • MERLN Institute for Technology-Inspired Regenerative Medicine, Complex Tissue Regeneration Department, Maastricht University, Maastricht, 6229 ER, the Netherlands.
  • Division of Pharmacology, Department of Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, 3584 CG, The Netherlands.

ORCID-Profile: Helen Kearney, Silvia M Mihăilă, Lorenzo Moroni, Carlos Mota

Förderung

  • Horizon 2020 Framework Programme
  • European Union's FET Open program

Zitieren

APA

Kearney, H., Mihăilă, S. M., Moroni, L., & Mota, C. (2026). Kidney Organoids in Drug Development: Integrating Technological Advances and Standardization for Effective Implementation. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202504719

Vancouver

Kearney H, Mihăilă SM, Moroni L, Mota C. Kidney Organoids in Drug Development: Integrating Technological Advances and Standardization for Effective Implementation. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202504719

BibTeX
@article{Kearney2026,
  author = {Kearney, Helen and Mihăilă, Silvia M and Moroni, Lorenzo and Mota, Carlos},
  title = {Kidney Organoids in Drug Development: Integrating Technological Advances and Standardization for Effective Implementation},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  doi = {10.1002/adhm.202504719}
}
Kostenlos starten →